Think local, deploy globally

Share this article:
Tim White
Tim White

Deploying digital frameworks across large pharmaceutical organizations is a tricky business, and sidestepping internecine turf battles and efficiency-sucking sour grapes requires securing local buy-in first, as Lundbeck's Tim White attested on the second day of eyeforpharma's Barcelona 2013 conference.

White, global director and head of customer interaction management at Lundbeck, related to industry delegates his experiences in implementing a global multichannel strategy at Novartis, where, until a few weeks ago, he spearheaded global digital commercialization. The idea was to standardize a multichannel platform whereby the global division would directly feed all content and information down to the local teams.

“The CEO stood on a stage and presented the project, saying ‘This is going to change the way we do business,” recalled White. “It all seemed very robust.”

But there was a small problem: the plan was not being adopted. “Individual countries were going against the strategy,” said White.

It seems local brand managers, typically proud of their efforts and hungry for recognition, were demoralized by the plans to bypass them. Agency partners, too, were irked at having been cut out of the content loop and even began pitching different systems to the local brand managers. As a result, not much was happening.

“We had reps waiting around with iPads and nothing to load onto them,” said White. “We were stuck at stage one.”

White and his team had made a mistake. “We had forgotten the simplicity aspect,” he said. “We built this incredibly complex system but we had forgotten the local level. It's the market that drives how we interact with our customers.”

So they wasted little time in meeting again with stakeholders, realizing “this was the beginning to solve the needs.” Soon after, version two appeared – again, a standardized framework, but with the flexibility to download content at global, regional and local levels.

Although White didn't stay at Novartis long enough to offer delegates any robust results, he said the new platform appeared to be “very successful”, particularly in southern Europe and Scandinavia.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...